Previous studies demonstrated that soluble mesothelin, with a sensitivity of 50 % and a specificity of 95 % (Robinson et al. 2003; Creaney et al. 2007), could be a relevant tumor marker and the baseline serum level of mesothelin is an independent predictor of overall survival (Hollevoet et al. 2011; Linch et al. 2014). This evidence concerns the gene MSLN and neoplasm.